Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk will test CagriSema's long-term efficacy in late-stage trial, clinicaltrials.gov entry shows
Novo Nordisk will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its ...
devdiscourse6h
Novo Nordisk Faces Scrutiny Over CagriSema Trials
Novo Nordisk is under investor pressure for transparency regarding their obesity drug CagriSema, after trial results disappointed. Patients report weight loss but side effects like nausea. Investors ...
Novo Nordisk says it has not yet posted details about new CagriSema trial
Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...
Novo Nordisk Hit With Suit for Underwhelming CagriSema Trial (1)
A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...
Novo Nordisk Shares Have a Long Road Back from 40% Slump
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
Novo Nordisk A/S Is Being Sued For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
devdiscourse4d
Novo Nordisk Commences Fresh Trials for CagriSema
Novo Nordisk announced further trials of its obesity drug, CagriSema, following unsatisfactory results from a previous phase. A new Phase III trial will assess long-term efficacy, launching on ...
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO
NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
Why Novo Nordisk Stock Jumped a Lucky 7.7% Today
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...
Yahoo Finance4d
Novo Nordisk Shares Have a Long Road Back from 40% Slump
The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot ...